Theravance Biopharma (TBPH) Misses Q1 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St set to gain on tech rebound, Middle East in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- Oil drops as Trump cancels planned strikes against Iran
- Intel rallies as BofA double-upgrades stock on increased CPU, foundry visibility
- Oppenheimer sees little strategic case for Tesla-SpaceX merger
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Axsome Therapeutics (AXSM) PT Raised to $380 at Jefferies
Theravance Biopharma (TBPH) Will Make VIBATIV Poster Presentation at ATS 2016
May 11, 2016 8:06 AM EDTTheravance Biopharma, Inc. (NASDAQ: TBPH) announced that new data on VIBATIV (telavancin), the Company's FDA-approved antibiotic, will be the focus of a poster presentation at the American Thoracic Society (ATS) 2016 International Conference. Researchers will present results from post hoc analyses of the previously completed Phase 3 ATTAIN (Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia) studies, registrational trials which supported the regulatory approval of telavancin (marketed as VIBATIV) for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP). The ATS 2016 International Conference is being held in San Francisco on May 13-18, 2016.
The... More
